Edwards Lifesciences Corp (NYSE:EW) Shares Purchased by Landscape Capital Management L.L.C.

Landscape Capital Management L.L.C. lifted its position in Edwards Lifesciences Corp (NYSE:EW) by 365.3% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 21,517 shares of the medical research company’s stock after purchasing an additional 16,893 shares during the quarter. Landscape Capital Management L.L.C.’s holdings in Edwards Lifesciences were worth $3,975,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in EW. Ledyard National Bank raised its stake in Edwards Lifesciences by 0.5% during the 2nd quarter. Ledyard National Bank now owns 9,178 shares of the medical research company’s stock valued at $1,696,000 after acquiring an additional 50 shares during the last quarter. Municipal Employees Retirement System of Michigan raised its stake in Edwards Lifesciences by 1.8% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 2,880 shares of the medical research company’s stock valued at $532,000 after acquiring an additional 50 shares during the last quarter. Tarbox Family Office Inc. raised its stake in Edwards Lifesciences by 48.7% during the 2nd quarter. Tarbox Family Office Inc. now owns 177 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 58 shares during the last quarter. Advisory Services Network LLC raised its stake in Edwards Lifesciences by 0.4% during the 2nd quarter. Advisory Services Network LLC now owns 14,932 shares of the medical research company’s stock valued at $2,759,000 after acquiring an additional 59 shares during the last quarter. Finally, BB&T Corp raised its stake in Edwards Lifesciences by 2.2% during the 1st quarter. BB&T Corp now owns 2,903 shares of the medical research company’s stock valued at $556,000 after acquiring an additional 63 shares during the last quarter. 82.43% of the stock is owned by hedge funds and other institutional investors.

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 3,000 shares of the stock in a transaction on Thursday, May 30th. The stock was sold at an average price of $169.60, for a total transaction of $508,800.00. Following the sale, the vice president now owns 20,674 shares in the company, valued at approximately $3,506,310.40. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Michael A. Mussallem sold 22,850 shares of the stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $184.27, for a total value of $4,210,569.50. Following the sale, the chief executive officer now owns 95,770 shares in the company, valued at approximately $17,647,537.90. The disclosure for this sale can be found here. Insiders sold a total of 142,948 shares of company stock valued at $27,936,332 over the last ninety days. 1.63% of the stock is currently owned by company insiders.

NYSE EW traded up $1.64 during mid-day trading on Thursday, hitting $215.15. The stock had a trading volume of 54,630 shares, compared to its average volume of 1,186,828. Edwards Lifesciences Corp has a 52-week low of $134.53 and a 52-week high of $219.71. The firm has a market cap of $44.90 billion, a P/E ratio of 45.79, a price-to-earnings-growth ratio of 2.72 and a beta of 0.87. The stock has a 50 day moving average price of $200.64. The company has a current ratio of 3.38, a quick ratio of 2.48 and a debt-to-equity ratio of 0.18.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, July 23rd. The medical research company reported $1.38 earnings per share for the quarter, beating the consensus estimate of $1.33 by $0.05. Edwards Lifesciences had a return on equity of 31.25% and a net margin of 18.29%. The firm had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.04 billion. During the same period last year, the business posted $1.24 EPS. Edwards Lifesciences’s quarterly revenue was up 15.2% on a year-over-year basis. Sell-side analysts expect that Edwards Lifesciences Corp will post 5.34 EPS for the current year.

Several research firms have commented on EW. Barclays upped their price objective on Edwards Lifesciences from $160.00 to $175.00 and gave the company an “underweight” rating in a research note on Wednesday, July 24th. Credit Suisse Group increased their target price on Edwards Lifesciences from $221.00 to $226.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Zacks Investment Research raised Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $232.00 target price for the company in a research note on Thursday, July 25th. Morgan Stanley increased their target price on Edwards Lifesciences from $210.00 to $228.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 24th. Finally, BMO Capital Markets increased their target price on Edwards Lifesciences from $204.00 to $224.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $204.74.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Further Reading: Stock Split

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.